


# CRISPR/Cas9 gene editing and TSHR knock-out to understand its correlation with Graves' Disease (GD).

Sailahari Mullapudi



# Background

- Graves' Disease - autoimmune hyperthyroidism
  - Body's immune system releases abnormal antibodies that acts like the TSHR and attacks the immune system
  - Overactive thyroid gland - Increased T4 levels and T3 levels

## TSHR Genetics

- Gene present on chromosome 14q31
- 10 exons on this gene
- 10th exon codes for the G protein complex which allows for the cascade of reactions leading to TSH production

# Deletion (Gene Knockout) of TSHR Protein

- **Biol. question:** TSHR under expression is pertinent for Graves' Disease (GD)
- **Hypothesis:** TSHR gene mutations can cause disorders associated with Graves' Disease (GD). Knocking out the gene can potentially improve pathological phenotype in patients.


## How to test:

- CRISPR/Cas9
  - TSHR deletion □ Nonsense-polypeptide


## K-562 cell line

- Lymphoblasts isolated from bone marrow of chronic myelogenous leukemia patient

# Deletion (Gene Knockout) of TSHR Protein



- Deletion → 107 bp
- 5 different isoforms
- sgRNA 1 → 23 bp



# Procedure

- Protocol:
  - K-562 cell line and would create a CRISPR/Cas-cell-suspension with the guide RNA and Cas9 protein
  - The cells would then be electroporated; this would result in a semi-permeable cell membrane, allowing the sgRNA and Cas9 protein into the cell
  - If cell pool results in no positive clones, the transfection process would be repeated, and the Cas9/gRNA master mix would be adjusted
  - Check for TSHR expression
- Next steps for this knockout protocol would be to conduct it in a sterile, laboratory environment.

# gRNA Efficiency

- Used a publicly available package CRISPRseek
- Calculates gRNA Efficiency for a given set of sequences and feature weight matrix
- Arguments
  - Sequence containing gRNA plus PAM (size of gRNA)
  - Indicates parallel processing abilities
  - Data frame (feature weight matrix) to calculate GC content

# Pseudocode

- GC content
  - Finding the length of the gRNA, filtering to the G and C content
  - $GC\ content = G\ content + C\ content$
- Feature weight matrix
  - First column containing significant features and the second column containing the weight of corresponding features
  - Features include low/high GC content in the gRNA sequence, G02 - G at second position of the sequence and GT02 - GT di-nucleotide at 2nd position of the sequence
- The output of the function is in the form of a data frame where the efficiency of the gRNA is this data frame multiplied with the feature weight

# Data Analysis

- Data when laboratory experimentation is conducted
  - Genomic DNA would be evaluated using PCR
  - To check for TSHR expression - immunostaining and western blot
    - Look up available antibodies for TSHR and do a protein analysis
- Data obtained from computation analysis
  - To calculate gRNA efficiency, a R package, CRISPRseek was used
    - All online datasets and other resources used are publicly available



# Results

- The predicted accuracy for the TSHR knockout was 32.9%
  - In comparison to the currently predicted industry average efficiency (knockout score) of 34%
  - The success rate of CRISPR experiments is dependent on the efficiency of the gRNA

# Discussion

- Future research can be conducted that studies therapeutic methods for potentially curing GD
  - Partial knockout of TSHR gene
  - CRISPR/Cas9 on Car-T cells

# References

- Nettore, I. C., Cacace, V., De Fusco, C., Colao, A., & Macchia, P. E. (2013). The molecular causes of thyroid dysgenesis: a systematic review. *Journal of endocrinological investigation*, 36(8), 654–664. <https://doi.org/10.3275/8973>
- Zaaber, I., Mestiri, S., Marmouch, H., Mahjoub, S., Abid, N., Hassine, M., Bel Hadj Jrad-Tensaout, B., & Said, K. (2014). Polymorphisms in TSHR and IL1RN genes and the risk and prognosis of Hashimoto's thyroiditis. *Autoimmunity*, 47(2), 113–118. <https://doi.org/10.3109/08916934.2013.866101>
- Davies, T. F., Yin, X., & Latif, R. (2010). The genetics of the thyroid stimulating hormone receptor: history and relevance. *Thyroid : official journal of the American Thyroid Association*, 20(7), 727–736. <https://doi.org/10.1089/thy.2010.1638>  
<https://www.webmd.com/women/understanding-graves-disease-basics><https://www.synthego.com/blog/crispr-knockout-score#conclusion-know-your-knockout-score-when-analyzing-your-crispr-edits>  
<https://www.pnas.org/content/113/5/1244>
- Brand, O. J., Barrett, J. C., Simmonds, M. J., Newby, P. R., McCabe, C. J., Bruce, C. K., Kysela, B., Carr-Smith, J. D., Brix, T., Hunt, P. J., Wiersinga, W. M., Hegedüs, L., Connell, J., Wass, J. A., Franklyn, J. A., Weetman, A. P., Heward, J. M., & Gough, S. C. (2009). Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. *Human molecular genetics*, 18(9), 1704–1713. <https://doi.org/10.1093/hmg/ddp087>
- Dechairo, B. M., Zabaneh, D., Collins, J., Brand, O., Dawson, G. J., Green, A. P., Mackay, I., Franklyn, J. A., Connell, J. M., Wass, J. A., Wiersinga, W. M., Hegedus, L., Brix, T., Robinson, B. G., Hunt, P. J., Weetman, A. P., Carey, A. H., & Gough, S. C. (2005). Association of the TSHR gene with Graves' disease: the first disease specific locus. *European journal of human genetics : EJHG*, 13(11), 1223–1230. <https://doi.org/10.1038/sj.ejhg.5201485>
- Jin J;Xu Y;Huo L;Ma L;Scott AW;Pizzi MP;Li Y;Wang Y;Yao X;Song S;Ajani JA; (n.d.). An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue. *PloS one*. Retrieved December 27, 2021, from <https://pubmed.ncbi.nlm.nih.gov/32053639/>